A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma

2008 ◽  
Vol 216 (2) ◽  
pp. 158-166 ◽  
Author(s):  
S Boeuf ◽  
P Kunz ◽  
T Hennig ◽  
B Lehner ◽  
PCW Hogendoorn ◽  
...  
2016 ◽  
Vol 45 ◽  
pp. 1-7 ◽  
Author(s):  
Hao Ho ◽  
Alyza M. Skaist ◽  
Aparna Pallavajjala ◽  
Raluca Yonescu ◽  
Denise Batista ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e20547-e20547
Author(s):  
Alejandro Herreros-Pomares ◽  
Juan Diego de Maya ◽  
Héctor Amado ◽  
Cristóbal Aguilar-Gallardo ◽  
Eva Escorihuela ◽  
...  

2011 ◽  
Vol 301 (3) ◽  
pp. R727-R745 ◽  
Author(s):  
Hady Felfly ◽  
Jin Xue ◽  
Alexander C. Zambon ◽  
Alysson Muotri ◽  
Dan Zhou ◽  
...  

Stem cells are a potential key strategy for treating neurodegenerative diseases in which the generation of new neurons is critical. A better understanding of the characteristics and molecular properties of neural stem cells (NSCs) and differentiated neurons can help with assessing neuronal maturity and, possibly, in devising better therapeutic strategies. We have performed an in-depth gene expression profiling study of murine NSCs and primary neurons derived from embryonic mouse brains. Microarray analysis revealed a neuron-specific gene expression signature that distinguishes primary neurons from NSCs, with elevated levels of transcripts involved in neuronal functions, such as neurite development and axon guidance in primary neurons and decreased levels of multiple cytokine transcripts. Among the differentially expressed genes, we found a statistically significant enrichment of genes in the ephrin, neurotrophin, CDK5, and actin pathways, which control multiple neuronal-specific functions. We then artificially blocked the cell cycle of NSCs with mitomycin C (MMC) and examined cellular morphology and gene expression signatures. Although these MMC-treated NSCs displayed a neuronal morphology and expressed some neuronal differentiation marker genes, their gene expression patterns were very different from primary neurons. We conclude that 1) fully differentiated mouse primary neurons display a specific neuronal gene expression signature; 2) cell cycle block at the S phase in NSCs with MMC does not induce the formation of fully differentiated neurons; 3) cytokines change their expression pattern during differentiation of NSCs into neurons; and 4) signaling pathways of ephrin, neurotrophin, CDK5, and actin, related to major neuronal features, are dynamically enriched in genes showing changes in expression level.


BMC Genomics ◽  
2009 ◽  
Vol 10 (1) ◽  
pp. 10 ◽  
Author(s):  
Said Assou ◽  
Doris Cerecedo ◽  
Sylvie Tondeur ◽  
Véronique Pantesco ◽  
Outi Hovatta ◽  
...  

Blood ◽  
2008 ◽  
Vol 111 (12) ◽  
pp. 5654-5662 ◽  
Author(s):  
Duane C. Hassane ◽  
Monica L. Guzman ◽  
Cheryl Corbett ◽  
Xiaojie Li ◽  
Ramzi Abboud ◽  
...  

Abstract Increasing evidence indicates that malignant stem cells are important for the pathogenesis of acute myelogenous leukemia (AML) and represent a reservoir of cells that drive the development of AML and relapse. Therefore, new treatment regimens are necessary to prevent relapse and improve therapeutic outcomes. Previous studies have shown that the sesquiterpene lactone, parthenolide (PTL), ablates bulk, progenitor, and stem AML cells while causing no appreciable toxicity to normal hematopoietic cells. Thus, PTL must evoke cellular responses capable of mediating AML selective cell death. Given recent advances in chemical genomics such as gene expression-based high-throughput screening (GE-HTS) and the Connectivity Map, we hypothesized that the gene expression signature resulting from treatment of primary AML with PTL could be used to search for similar signatures in publicly available gene expression profiles deposited into the Gene Expression Omnibus (GEO). We therefore devised a broad in silico screen of the GEO database using the PTL gene expression signature as a template and discovered 2 new agents, celastrol and 4-hydroxy-2-nonenal, that effectively eradicate AML at the bulk, progenitor, and stem cell level. These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets.


PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0141066 ◽  
Author(s):  
Brian W. Busser ◽  
Yongshun Lin ◽  
Yanqin Yang ◽  
Jun Zhu ◽  
Guokai Chen ◽  
...  

2021 ◽  
Author(s):  
Xiaoling Huang ◽  
Yue Xu ◽  
Qian Zhao ◽  
Wenjing Ma ◽  
Pengfei Liu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document